You can buy or sell Verona Pharma and other stocks, options, ETFs, and crypto commission-free!
Verona Pharma plc American Depositary Share, also called Verona Pharma, is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. Verona Pharma's product include, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Read More Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, United Kingdom.
London, London & South East
52 Week High
52 Week Low
Markets InsiderMar 4
Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPD
Single dose of ensifentrine DPI formulation produced statistically significant and clinically meaningful dose-dependent bronchodilator response and was well tolerated at all doses Data support initiation of part 2 of study to evaluate effect of ensifentrine DPI formulation over one week of treatment First study to show efficacy of DPI formulation; Delivery via DPI could dramatically expand the clinical utility and commercial opportunity for ensifentrine in COPD and asthma LONDON, March 04, 2019 (GL...
Guru FocusFeb 28
Verona Pharma to Present at Cowen and Company 39th Annual Health Care Conference
LONDON, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) ( VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today announces that the Company’s management team will present and conduct face-to-face meetings at the Cowen and Company 39th Annual Health Care Conference. Jan-Anders Karlsson, PhD, CEO of Verona Pharma, is scheduled to present on Wednesday, March 13th at 10:00 am ET. A webca...
Markets InsiderFeb 20
Verona Pharma to Announce Financial Results for Full Year ended December 31, 2018 and Provide Clinical Development Update
LONDON, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it will report its audited financial results for the full year ended December 31, 2018 on Tuesday, February 26, 2019. Verona Pharma will host an investment community conference call at 8:00 a.m. Eastern Standard Time (2:00 p.m. Greenwich Mean Time) on Tuesd...
Expected May 7, Pre-Market